by Cal Strode | Jan 20, 2025
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific...
by Tyler Wenzel | Jan 16, 2025
Regenerative medicine, the biomedical field that includes the development of cell and gene therapies, is arguably the most exciting research discipline. I often reflect on how lucky I am to have found myself in this area of science. I am always excited to learn and...
by Lyla El-Fayomi | Dec 26, 2024
Pick of the Month Another HIV-1 remission, but with a twist: The Geneva Patient I previously wrote about Mr. Paul Edmonds, who was the fifth person in history to be cured of both HIV-1 and leukemia since the first such case in 2009. This was achieved through a...
by Sara M. Nolte | Dec 19, 2024
I’m excited to be sharing some new Canadian cancer immunotherapy developments! We’ve already seen some great stuff with CAR T cells and checkpoint inhibitors. But the strength of these therapies is also their downfall: their targets make them highly specific and...
by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
by Stacey Johnson | Nov 29, 2024
Are you familiar with the Gartner Hype Cycle? It’s a way of separating reality from hype when it comes to emerging technologies – like cell and gene therapies (CGTs). The hype cycle employs a graph to present the maturity of new technologies as they pass through five...
Comments